|
BeiGene Provides Update on Phase 2 Clinical Trial of Zanubrutinib in Patients with COVID-19-Related Pulmonary Distress
|
Trial did not meet the co-primary efficacy endpoints; no new safety signals identified CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)--$BGNE #BTKi--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a global biotechnology company focused on developing and commer...
Full "IntellAsia: Resources" article
|
|